Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Carlomagno

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|May 1, 2013
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradationGnana Prakasam Krishnamoorthy, Teresa Guida, Luigi Alfano, et al.
Plos One|January 18, 2013
Structure prediction and validation of the ERK8 kinase domainAngela Strambi, Mattia Mori, Matteo Rossi, et al.
Scientific Reports|November 25, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteinsMarialuisa Moccia, Lingzhi Zhang, Zhengyu Wang, et al.
Cancer Research|June 17, 2006
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteinsAngela Iervolino, Rodolfo Iuliano, Francesco Trapasso, et al.
Oncogene|June 9, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsFrancesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutantsTeresa Guida, Suresh Anaganti, Livia Provitera, et al.
Endocrine-Related Cancer|November 26, 2008
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474Francesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)Francesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
Cancer Research|February 28, 2002
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenesFrancesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
The Journal of Biological Chemistry|February 18, 2006
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogeneCarlo Iavarone, Mario Acunzo, Francesca Carlomagno, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|May 1, 2013
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradationGnana Prakasam Krishnamoorthy, Teresa Guida, Luigi Alfano, et al.
Plos One|January 18, 2013
Structure prediction and validation of the ERK8 kinase domainAngela Strambi, Mattia Mori, Matteo Rossi, et al.
Scientific Reports|November 25, 2025
Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteinsMarialuisa Moccia, Lingzhi Zhang, Zhengyu Wang, et al.
Cancer Research|June 17, 2006
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteinsAngela Iervolino, Rodolfo Iuliano, Francesco Trapasso, et al.
Oncogene|June 9, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsFrancesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutantsTeresa Guida, Suresh Anaganti, Livia Provitera, et al.
Endocrine-Related Cancer|November 26, 2008
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474Francesca Carlomagno, Teresa Guida, Suresh Anaganti, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)Francesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
Cancer Research|February 28, 2002
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenesFrancesca Carlomagno, Donata Vitagliano, Teresa Guida, et al.
The Journal of Biological Chemistry|February 18, 2006
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogeneCarlo Iavarone, Mario Acunzo, Francesca Carlomagno, et al.
Pageof 7